Nervous system
Cholinesterase inhibitors (for dementia)
Drugs that slow the breakdown of acetylcholine in the brain, partly compensating for the loss of cholinergic neurons in Alzheimer disease; they modestly improve symptoms but do not stop the disease.
Mécanisme d’action
- Alzheimer disease destroys cholinergic neurons of the basal forebrain early, depriving the cortex and hippocampus of acetylcholine.
- Donepezil, rivastigmine and galantamine reversibly inhibit acetylcholinesterase in the brain (rivastigmine also butyrylcholinesterase).
- Acetylcholine lasts longer in the synapse, modestly improving memory and function for a time.
- They also act on peripheral cholinergic synapses: heart, gut and bronchi.
Cibles moléculaires
- Acetylcholinesterase: Reversible inhibitor
Médicaments : Cholinesterase inhibitors (for dementia)
- Donepezil (Once daily.)
- Rivastigmine (Also as a skin patch.)
- Galantamine
Indications thérapeutiques
- Mild to moderate, and with donepezil severe, Alzheimer disease
- Dementia in Parkinson disease (rivastigmine)
Maladies traitées
Effets indésirables
- Nausea, vomiting, diarrhoea and weight loss
- Bradycardia and syncope
- Vivid dreams and insomnia
- Muscle cramps
Contre-indications selon le terrain
- Bradycardia or heart block (Avec précaution): Increased vagal tone slows the heart further and can cause fainting.
- Bronchial asthma (Avec précaution): Acetylcholine constricts the bronchi and increases secretions.
- Peptic ulcer disease (Avec précaution): Cholinergic stimulation increases gastric acid secretion.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 8, Drugs for Neurodegenerative Diseases, Drugs used in Alzheimer disease
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 60, Special Aspects of Geriatric Pharmacology, Alzheimer disease
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.